CDK4 and breast carcinoma: This is exemplified by PIK3CA mutations in 30%–40% of HR+ breast cancers, driving constitutive PI3K pathway activation and conferring dual resistance to CDK4/6 inhibitors and endocrine therapies (Abu-Khalaf et al., 2023).